Dr Urszula McClurg
- Email: email@example.com
- Telephone: +44(0)01912226845
- Fax: +44(0)1912087424
- Address: Institute for Cell and Molecular Bioscience
Newcastle upon Tyne
Tyne and Wear
2013 PhD Molecular Medicine,
Leeds Institute of Molecular Medicine (LIMM), University of Leeds
2008 MSc (Hons) Biomedical Sciences,
University of Bradford
2007 BSc (Hons) Biology,
University of Lodz, Poland
British Association for Cancer Research (BACR)
European Association for Cancer Research (EACR)
Markers of esteem:
Independent financial support:
1. £21,916 CRUK - personal travel fellowship. (2016)
3. £37,751 MRC CiC – co-applicant. (2015)
4. £65,384 JGWP Foundation – lead applicant. (2016)
5. £49,746 JRESC – co-applicant. (2015)
Additional markers of esteem:
• Best poster - International Androgens meeting, Innsbruck. (2016)
• Fellowship for CRUK Bioinformatics Summer School. (2016)
• Runner-up best speaker - Leeds University Postgraduate symposium. (2010)
• FP6 EU fellowship - training in ubiquitination at Karolinska Institute. (2010)
• Award for the best MSc of the year. (2008)
• Socrates ERASMUS scholarship. (2006)
1. RNA sequencing workshop, Newcastle, UK. (2016)
2. BAUS Academic Section at SARS, Cambridge. (2014)3. The ubiquitin-proteasome system in health and disease meeting, Stockholm. (2010)
Cancer remains one of the main focus areas of translational research as it is predicted that 50% of the population will experience this disease at some point in their lifetime. Even though major progress has been made in cancer diagnosis and treatment it still remains the second leading cause of death with 8.4 million deaths recorded worldwide in 2012. Consequently, understanding the molecular mechanisms behind cancer development and progression is crucial for developing effective treatments and discovering valuable biomarkers.
Meiosis-associated proteins have never been explored in the context of cancer research as their expression is thought to be tightly controlled and restricted to meiotic cells. We have recently discovered that, contrary to accepted knowledge, a group of meiotic proteins is expressed in a variety of human cancer models. More importantly, our analysis of multiple large datasets of patient cancer samples reveals that these proteins are expressed in the majority of cancer patients and that their levels are predictive of cancer outcome and disease progression. Our work focuses on validating these meiosis-associated proteins as biomarkers in cancer stratification and determining their role in cancer progression. Identifying new oncogenes and pathways of carcinogenesis could provide novel therapeutic strategies.
- McClurg UL, Cork DMW, Darby S, Ryan-Munden CA, Nakjang S, Mendes-Cortes L, Treumann A, Gaughan L, Robson CN. Identification of a novel K311 ubiquitination site critical for androgen receptor transcriptional activity. Nucleis Acids Research 2017, 45(4), 1793-1804.
- Nabbi A, McClurg UL, Thalappilly S, Almami A, Mobahat M, Bismar TA, Binda O, Riabowol K. ING3 promotes prostate cancer growth by activating the androgen receptor. BMC medicine 2017, 15(1), 103.
- Munkley J, McClurg UL, Livermore KE, Ehrmann I, Knight B, McCullagh P, McGrath J, Crundwell M, Harries LW, Leung HY, Mills IG, Robson CN, Rajan P, Elliott DJ. The cancer-associated cell migration protein TSPAN1 is under control of androgens and its upregulation increases prostate cancer cell migration. Scientific Reports 2017, 7(1), 5249.
- McClurg U, Dransfield D, Namdev N, Jacoby D, Chit N, Nakjang S, Edwards J, McCracken S, Robson C. A novel anti-androgen candidate galeterone acts by targeting USP12, a deubiquitinating enzyme that controls prostate cancer growth and survival. In: 28th EORTC – NCI – AACR Symposium on Molecular Targets and Cancer Therapeutics. 2016, Munich, Germany: Elsevier.
- Kim S, Natesan S, Cornilescu G, Carlson S, Tonelli M, McClurg UL, Binda O, Robson CN, Markley JL, Balaz S, Glass KC. Mechanism of Histone H3K4me3 Recognition by the Plant Homeodomain of Inhibitor of Growth 3. Journal of Biological Chemistry 2016, 291(35), 18326-18341.
- Logan IR, McClurg UL, Jones DL, O'Neill DJ, Shaheen FS, Lunec J, Gaughan L, Robson CN. Nutlin-3 inhibits androgen receptor-driven c-FLIP expression, resulting in apoptosis of prostate cancer cells. Oncotarget 2016, 7(46), 74724-74733.
- McClurg UL, Robson CN. Deubiquitinating enzymes as oncotargets. Oncotarget 2015, 6(12), 9657-9668.
- McClurg UL, Danjo K, King HO, Scott GB, Robinson PA, Crabtree JE. Epithelial cell ADAM17 activation by Helicobacter pylori: role of ADAM17 C-terminus and Threonine-735 phosphorylation. Microbes and Infection 2015, 17(3), 205–214.
- Munkley J, Livermore KE, McClurg UL, Kalna G, Knight B, McCullagh P, McGrath J, Crundwell M, Leung HY, Robson CN, Harries LW, Rajan P, Elliott DJ. The PI3K regulatory subunit gene PIK3R1 is under direct control of androgens and repressed in prostate cancer cells. Oncoscience 2015, 2(9).
- McClurg UL, Harle VJ, Nabbi A, Batalha-Pereira A, Walker S, Coffey K, Gaughan L, McCracken SRC, Robson CN. Ubiquitin-specific protease 12 interacting partners Uaf-1 and WDR20 are potential therapeutic targets in prostate cancer. Oncotarget 2015, 6(35).
- McClurg UL, Summerscales EE, Harle VJ, Gaughan L, Robson CN. Deubiquitinating enzyme Usp12 regulates the interaction between the androgen receptor and the Akt pathway. Oncotarget 2014, 5(16), 7081-7092.
- Burska UL, Fletcher JN. Two plasmid-encoded genes of enteropathogenic Escherichia coli strain K798 promote invasion and survival within HEp-2 cells. APMIS 2014, 122(10), 922-930.
- Burska UL, Harle VJ, Coffey K, Darby S, Ramsey H, Gaughan L, Robson CN. Usp12 a novel AR co-regulator and PCa biomarker?. In: Society of Academic and Research Surgery Annual Meeting. 2014, Cambridge, UK: Wiley-Blackwell Publishing.
- Burska UL, Harle VJ, Coffey K, Darby S, Ramsey H, O'Neill D, Logan IR, Gaughan L, Robson CN. Deubiquitinating Enzyme Usp12 Is a Novel Co-activator of the Androgen Receptor. Journal of Biological Chemistry 2013, 288(45), 32641-32650.